In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach

Area of Science:

• Pharmacometrics
• Computational Biology
• Antiviral Drug Development

Background:

• Paxlovid is an orally bioavailable antiviral for SARS-CoV-2.
• Understanding its pharmacometric features is crucial for optimizing treatment.
• Existing research highlights its promising safety profile.

Purpose of the Study:

• To explore the pharmacometric features of Paxlovid using a hybrid multiscale mathematical approach.
• To validate the model's accuracy against in vitro and in vivo data.
• To investigate the impact of early intervention timing on SARS-CoV-2 progression.

Main Methods:

• Development of a hybrid multiscale mathematical model for Paxlovid.
• In silico simulation of Paxlovid's pharmacometrics.
• Validation of model predictions against in vitro experimental outcomes.
• Assessment of nirmatrelvir and ritonavir components in a simplified in vivo model.

Main Results:

• The mathematical model accurately replicated in vitro experimental results.
• The model confirmed the sufficiency and necessity of nirmatrelvir and ritonavir.
• Early intervention with Paxlovid was shown to be critical in simulations.
• A specific time window was identified where treatment delays cause maximal tissue damage.

Conclusions:

• The developed mathematical model provides a robust tool for assessing Paxlovid's pharmacometrics.
• Simulations underscore the importance of timely SARS-CoV-2 treatment with Paxlovid.
• The study highlights the critical role of both nirmatrelvir and ritonavir in the drug's efficacy.